Cardiology

Trials, guidelines and practice across cardiovascular medicine.

Tirzepatide lowered HF and MACE-4 rates vs dulaglutide in SURPASS-CVOT

SURPASS-CVOT subgroup analysis found lower composite death or HF events and MACE-4 with tirzepatide versus dulaglutide in patients with heart failure.

By Dr. Aishwarya N., MBBS · Oct 17, 2026 · 5 min read

Cardiology·NIH

Blood Pressure Drug May Activate Brown Fat in Retrospective Study

A large retrospective study links a blood-pressure drug, likely losartan, with brown fat activity that may influence cardiovascular…

Oct 17, 2026

Cardiology·AHA

Hispanic representation and heart health face widening U.S. gaps

AHA report finds cardiovascular disease now leads deaths among Hispanic adults, while Hispanic clinicians remain underrepresented in care…

Oct 17, 2026

Cardiology·AHA

Extreme Heat Raises Cardiovascular Risk, AHA Warns

Extreme heat can strain the heart, worsen dehydration and trigger emergencies. The AHA outlines warning signs and practical…

Oct 17, 2026

Cardiology·AHA

2025 Blood Pressure Guideline Pushes Earlier Treatment and Prevention

AHA and ACC update blood pressure guidance with earlier treatment, PREVENT risk scoring, lifestyle targets, and stronger pregnancy…

Oct 17, 2026

Cardiology·ACC-PRO

FDA issues early alert on Edwards mitral valve delivery system after death, injury

FDA issued an early alert for Edwards Lifesciences’ mitral valve delivery system after reports of a death and…

Oct 17, 2026

Cardiology·JCI

Pediatric anthracycline cardiomyopathy linked to cellular senescence in heart tissue

Single-nuclei RNA sequencing of pediatric heart tissue found a senescence signature in anthracycline cardiomyopathy across cardiomyocytes and nonmyocytes.

Oct 17, 2026

Cardiology·AHA